title: Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukaemia in first remission: a prospective controlled trial.
abstract: In 1982 we began a prospective controlled trial to assess the effectiveness of allogeneic bone marrow transplantation and intensive post-remission chemotherapy for patients with acute myelogenous leukaemia in first complete remission. Fourteen patients, 3-45 years of age, who had an HLA-identical sibling donor, received bone marrow transplantation. Twenty-five patients who either lacked an HLA-identical sibling or were over 45 years of age received intensive consolidation chemotherapy including high-dose cytosine arabinoside with or without adriamycin. The actuarial rate of continued complete remission (CCR) at 3 years was significantly higher in the transplantation group than in the chemotherapy group: 70% (95% confidence interval 35-91%) compared with 10% (95% confidence interval 2-30%); P = 0.01. However, the actuarial rate of CCR was not significantly different between the transplantation group and patients under 45 years in the chemotherapy group: 70% (95% confidence interval 35-91%) compared with 17% (95% confidence interval 4-45%), 0.1 greater than P greater than 0.05. The actuarial probability of leukaemia relapse was significantly lower in the transplantation group than in the chemotherapy group: 10% (95% confidence interval 4-21%) compared with 88% (95% confidence interval 70-96%), 0.005 greater than P greater than 0.001. There was no significant difference between both groups if we compare only the patients who died of non-leukaemic causes: 22% (95% confidence interval 9-42%) versus 25% (95% confidence interval 7-59%), P = NS. In summary, this study shows that allogeneic bone marrow transplantation is a better anti-leukaemic treatment than is intensive consolidation chemotherapy in patients with AML in first complete remission.
authors.affiliation: Haematology Department, Hospital Nacional Marqués de Valdecilla, Faculty of Medicine, University of Cantabria, Santander, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Conde
authors.forename: A
authors.initials: A
authors.lastname: Iriondo
authors.forename: C
authors.initials: C
authors.lastname: Rayon
authors.forename: C
authors.initials: C
authors.lastname: Richard
authors.forename: E
authors.initials: E
authors.lastname: Fanjul
authors.forename: J
authors.initials: J
authors.lastname: Garijo
authors.forename: V
authors.initials: V
authors.lastname: Hermosa
authors.forename: A
authors.initials: A
authors.lastname: Coma
authors.forename: C
authors.initials: C
authors.lastname: Bello
authors.forename: D
authors.initials: D
authors.lastname: Carrera
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011336:Probability; D011446:Prospective Studies; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D004317:Doxorubicin